* Iteos Therapeutics Inc ITOS.OQ reported a quarterly
adjusted
loss of 18 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -96 cents. The mean expectation of
five analysts for the quarter was for a loss of $1.04 per share.
Wall Street expected results to range from $-1.15 to -80 cents
per share.
* Revenue was $35.00 million; analysts expected $1.00
million.
* Iteos Therapeutics Inc's reported EPS for the quarter was
a loss
of 18 cents.
* The company reported a quarterly loss of $7.13 million.
* Iteos Therapeutics Inc shares had risen by 2.6% this
quarter and
gained 39.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 16.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Iteos
Therapeutics Inc is $41.00
This summary was machine generated from LSEG data August 8 at
01:03 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.04 -0.18 Beat
Jan. 1 0001 -1.26 -1.07 Beat
Dec. 31 2023 -1.03 -0.85 Beat
Sep. 30 2023 -1.20 -0.90 Beat